|Bid||36.30 x 1000|
|Ask||38.72 x 2900|
|Day's range||38.19 - 38.29|
|52-week range||29.39 - 47.82|
|PE ratio (TTM)||28.28|
|Earnings date||7 Aug 2018 - 13 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||49.05|
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
Britain's Indivior (Frankfurt: 2IVA.F - news) said on Friday it would pursue all legal remedies, including seeking an immediate injunction against the U.S Food and Drug Administration's (FDA) decision to approve the first generic versions of Suboxone Film, an opioid addiction treatment. Indivior, which was spun out from Reckitt Benckiser (Xetra: A0M1W6 - news) in 2014, stuck to its 2018 guidance saying that until the details of Dr. Reddy's market entry of the drug's generic version is confirmed.
Britain's Indivior (Frankfurt: 2IVA.F - news) fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue. Shares (Berlin: DI6.BE - news) in Indivior, which was spun out from Reckitt Benckiser in 2014, were down 22.7 percent at 0925 GMT and the biggest loser on the FTSE midcap index. India's Dr Reddy's Laboratories received FDA approval for a copy-cat version of the treatment, which has been rapidly losing market share due to competition from generics.
U.S. regulators have approved the first generic version of an under-the-tongue film for treating opioid addiction.
The Dow Jones Industrial Average finished lower today, but the other major indexes fared better. •...and explain why Twitter (TWTR) soared. The S&P 500 has come to a standstill, but don't expect it to stay that way for long.
The U.S. Food and Drug Administration late Thursday said it approved the first generic version of a Suboxone under-the-tongue film for the treatment of opioid addiction. Mylan Technologies Inc., a subsidiary ...
Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.
On June 13, Mylan (MYL) announced that the FDA didn’t approve its generic version of GlaxoSmithKline’s (GSK) Advair Diskus, an asthma drug and inhaler combination. The FDA cited “minor deficiencies” in Mylan’s ANDA (abbreviated new drug application) for its generic Advair, which was first dismissed by the FDA in March 2017.
Investors didn't cut Mylan any slack Thursday after the company announced U.S. regulators would likely delay its generic version of blockbuster asthma inhaler Advair.
** Shares of Mylan NV down 4.4 pct to $39.83 in Thurs trading ** Co late on Wed said U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug ...
Mylan and Oracle dragged on early trade, but positive news out of Europe sent futures higher, and IPOs Etsy, Huya and Pivotal were poised to nail news highs.
Mylan shares plunged late Wednesday after the FDA identified "minor deficiencies" in its application for a generic copy of GlaxoSmithKline's drug Advair.
Thomson Reuters(Reuters) - U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.
As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.
Being first to market helps Mylan, as does the competitive landscape for Neulasta biosimilarsBloomberg NewsHeather Bresch, chief executive officer of Mylan, speaks during an interview in New York in 2016. Mylan NV marked a major success late Monday with the first U.S. approval of a biosimilar version of Neulasta, an anti-infective used for patients undergoing cancer treatment. Biosimilar drugs are copycat versions of expensive biologic drugs, which treat complex diseases like cancer, multiple sclerosis and diabetes.
Mylan spiked to a nearly eight-week high Tuesday after the FDA approved its copycat drug to Amgen's blockbuster medication Neulasta, a treatment that is used to stimulate bone marrow.
Stocks that moved substantially or traded heavily Tuesday: Starbucks Corp., down $1.39 to $55.68 Howard Schultz is stepping down as the coffee chain's executive chairman. G-III Apparel Group Ltd., up $4.65 ...